Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection poses a significant global health burden, particularly in Africa, the Middle East, and Asia.
• HCV genotypes 4, 5, and 6 are prevalent in these regions, yet literature on their characteristics remains limited.

Purpose of the Study:

• To review and synthesize the available characteristics of patients infected with HCV genotypes 4, 5, and 6.
• To provide an overview of treatment outcomes for these less-common HCV genotypes.

Main Methods:

• A comprehensive literature search was conducted using PubMed, combining terms for 'hepatitis C' with 'genotype 4', 'genotype 5', and 'genotype 6'.
• Relevant articles identified through the search were critically reviewed to extract key information.

Main Results:

• Unsafe medical practices are the primary cause of HCV genotypes 4, 5, and 6 in endemic areas, contrasting with intravenous drug use in developed nations.
• Pegylated interferon and ribavirin for 48 weeks yields sustained virological response (SVR) rates of 40-70% for genotype 4, 60-70% for genotype 5, and 70-80% for genotype 6.
• Preliminary data indicate a potential 24-week treatment course with pegylated interferon and ribavirin may achieve approximately 70% SVR for genotype 6.

Conclusions:

• The current standard of care for HCV genotypes 4, 5, and 6 involves 48 weeks of pegylated interferon and ribavirin.
• A shortened 24-week therapy duration may be a viable option for patients with HCV genotype 6.
• The development of novel, more effective therapies for HCV is anticipated in the near future.